This executive summary, excerpted from AVAC Report 2014/15, puts the current discussion about global targets for ending AIDS in context. What makes a good target? What targets have worked in the past—and why? What is the state of HIV prevention targets and plans today?
AVAC Report 2014/15: Prevention on the Line [Executive Summary]
Biomedical HIV Prevention Efficacy Trials, 2014–2016
Hormonal Contraceptives and HIV – An introductory fact sheet
This introductory 3-page document summarizes the debate over whether certain hormonal contraceptives increase women’s risk of HIV acquisition. For more basic fact sheets, visit www.avac.org/intro.
Regulatory Mapping Project
AVAC undertook this review of activities designed to strengthen regulatory capacity, particularly in Africa. This included a desk review of various planned or ongoing activities and interviews with key informants. The results are summarized by country, initiative, and objective among other parameters.
Essential Actions for HIV Prevention Research Rollout 2014/15
This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.
FY2015 US Global AIDS Budget Plan: The Human Impact
The US government’s efforts to fight the global AIDS pandemic through both the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to Fight AIDS, Tuberculosis and Malaria have been transformative in the global AIDS response. To maintain the current total level of US global HIV/AIDS funding in Fiscal Year 2015, the US House of Representatives has proposed restoring US$300 million in PEPFAR funding. As illustrated in this infographic, amfAR has estimated the potential human impact of US$300 million to expand lifesaving HIV prevention, Treatment U=U and care services.
PrEP by the Numbers: Efficacy, regulatory approval and more
PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.
The Number of Microbicide Trials Currently Underway
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the number of ongoing microbicide trials in each phase of study.
Tracking Investments and Expenditures in HIV Prevention Research and Development: Sustaining Funding in a Shifting International Development Landscape
This infographic shows the shifting landscape of HIV R&D. It emphasizes that funding is decreasing and that priorities are changing. This poster was presented in 2014 at the HIV Research for Prevention (R4P) conference in South Africa.
Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis
This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.